We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Crystal Amber Fund Limited | LSE:CRS | London | Ordinary Share | GG00B1Z2SL48 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 77.50 | 76.00 | 79.00 | 77.50 | 77.50 | 77.50 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | -2.14M | -5.58M | -0.0723 | -10.72 | 59.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2024 21:06 | That final line is truly shocking. Since 1993, obese proportion up from 14.9% to 28%. One in seven becomes two in seven. | wbodger | |
21/4/2024 09:20 | Slightly more scientific appraisal of Morphic Medicals EndoBarrierPresented by Bob Ryderhttps://abcd.ca | kooba | |
18/4/2024 07:53 | Bernstein tweet ..seems Morphic getting some attention.https://x. | kooba | |
12/4/2024 04:46 | Morphic got a brief mention in this review: Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes? CRS have most of their eggs in that basket. | mobark2 | |
27/2/2024 10:28 | I set an alert for 85p ages ago .... just got triggered. Director's Dealings? Crystal Amber Fund was notified on 26 February 2024 that the Investment Manager, Crystal Amber Asset Management (Guernsey) Limited, a PDMR of the Company, sold 600,000 Ordinary Shares in the Company on 26 February 2024. Following this transaction, Crystal Amber Asset Management (Guernsey) Limited holds 6,299,031 Ordinary Shares (equivalent to 8.16 per cent. of the Company's voting rights). | peterbill | |
24/1/2024 11:54 | There are five trading days up to and including next Tuesday and up to last night about half the £5 million had been spent. Since the AGM motion authorised repurchases up to 15% of capital they are not close to that limit so it could restart again should the share price drop back after they spend the remaining £2.5 million. They just need to find a few more quid down the cushions. The authorisation remains until the 2024 GM. Any sign of movement in DLAR, Prax or Morphic? Just musing ... | wbodger | |
23/1/2024 09:50 | I've always believed they would have to include a discounted value of the possible future revenue streams in NAV for the DCUs. That was originally anything from zero up to an additional 2.98 pence per share eventually (based on hope/guesswork) of which they have only had 0.309 pence so far. £0.00309 times 575 million is the £1.8 million. They need Prax to find a project to produce Lancaster profits to get it up the 2.98 pps. I don't know if they have. If they do find one it should help the discounted value. Question for the Board though. | wbodger | |
23/1/2024 09:09 | I've sold out now. The discount to NAV is still large but the temporary buyback is at an end - which seemed to give a big push to the recent price rise. Will wait and see. GLA | briggs1209 | |
23/1/2024 05:26 | Thanks for your answer @wbodger but I mean all the future payments that have been agreed but not yet paid. Must be a considerable amount. | mobark2 | |
22/1/2024 23:19 | Yes, paid in September or October. The next one is due in March. The September payment was £1.8 million. (See Chairman's report in Results for year ending June 2023, announced 25 October 2023. Says £1.8 million was "banked" earlier in the month.) | wbodger | |
22/1/2024 21:27 | Does the CRS NAV include expected payments from PRAX? | mobark2 | |
22/1/2024 17:45 | End-December NAV 106.08 pence(30 November 2023: 99.6 pence per share). Effect of improvement in DLAR shareprice I suppose. Shares bought for 79 pence are at a 25% discount to intrinsic value per CA. | wbodger | |
04/1/2024 16:44 | 79p now being paid for shares. oh yeah :) | thelongandtheshortandthetall | |
21/12/2023 00:06 | All about the current share but back. £5m can be spent up to the 30th Jan. 5 weeks! £5m is a whack of buying pressure imo. | thelongandtheshortandthetall | |
20/12/2023 23:35 | 55p since the beginning of last year | agnes | |
20/12/2023 20:27 | Does this fund pay a dividend? | r9505571 | |
15/12/2023 16:30 | ^sort of puts a floor under the share price IMO. Not a bad thing.. :0) £5m protection to the downside. | thelongandtheshortandthetall | |
08/12/2023 16:34 | hmm, they can only buy at 105% of the middle market position for the five previous days. I reckon the recent price is about 63p so they can only buy up to 66p at the moment. topped up with another chunk today. Buy back could kick in by mid way through next week if 66p holds | briggs1209 | |
08/12/2023 15:02 | I'm pleasantly surprised that they are doubling down on their estimate of NAV. DLAR has been strong but there is only Morphic to make up the difference between the claimed NAV and the market share price Allied Minds could surprise I suppose but not more than 5 to 10 pence with a very fair wind. DLAR getting an offer would be very helpful. | wbodger | |
08/12/2023 14:42 | See from oost 822 that it is.... Wow | gemlotte55 | |
08/12/2023 14:35 | Is it till the end of January purchases to be made by? | gemlotte55 | |
08/12/2023 14:31 | I think you are reading it right..these could easily be walked up if Winterflood push the pedal, if no meaningful seller emerges then should move higher..imagine it is in Wins interest to get it done. | kooba |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions